The goal of this research is to find out how safe and potentially effective the new drug SAR442168 is for the treatment of participants with the secondary progressive form of multiple sclerosis (SPMS). The research drug is taken orally in the form of a tablet.
18 - 60 years
Secondary progressive form of multiple sclerosis (SPMS)
2 to 4 years